This is a working overview of LC-MS/MS, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-07-19 and is reviewed periodically as new material appears.
SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
Identity and purity of SR9009 samples are usually checked with chromatographic and spectrometric methods. High-performance liquid chromatography can separate the compound from related impurities, while mass spectrometry provides molecular mass confirmation. Nuclear magnetic resonance spectroscopy may be used for structural verification in research settings. No single method proves biological activity, and certificates of analysis should be reviewed alongside raw data. Independent testing is often needed because online products vary widely.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
| Property | Value | Notes |
|---|---|---|
| Synonyms | SR9009; Stenabolic | Stenabolic is an informal name |
| Common form | Crystalline powder | Supplied in milligram to gram quantities |
| Long-term storage | -20 °C, desiccated, protected from light | Reduces degradation |
| Detection technique | LC-MS/MS | Common in anti-doping and research analysis |
| Regulatory status | Prohibited in sport by WADA | Not approved for human therapeutic use |
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
=== Mechanical bonding effects on non-covalent interactions === The strength of non-covalent interactions in a mechanically interlocked molecular architecture increases as compared to the non-mechanically bonded analogues. This increased strength is demonstrated by the necessity of harsher conditions to remove a metal template ion from catenanes as opposed to their non-mechanically bonded analogues. This effect is referred to as the "catenand effect". The augmented non-covalent interactions in interlocked systems compared to non-interlocked systems has found utility in the strong and selective binding of a range of charged species, enabling the development of interlocked systems for the extraction of a range of salts. This increase in strength of non-covalent interactions is attributed to the loss of degrees of freedom upon the formation of a mechanical bond. The increase in strength of non-covalent interactions is more pronounced on smaller interlocked systems, where more degrees of freedom are lost, as compared to larger mechanically interlocked systems where the change in degrees of freedom is lower. Therefore, if the ring in a rotaxane is made smaller the strength of non-covalent interactions increases, the same effect is observed if the thread is made smaller as well.
PRRT radiopharmaceuticals are constructed with three components; the radionuclide, chelator, and somatostatin analogue (peptide). The radionuclide delivers the actual therapeutic effect (or emission, such as photons, for imaging). The chelator is the essential link between the radionuclide and peptide. For 177Lu and 90Y this is typically DOTA (tetracarboxylic acid, and its variants) and DTPA (pentetic acid) for 111In. Other chelators known as NOTA (triazacyclononane triacetic acid) and HYNIC (hydrazinonicotinamide) have also been experimented with, albeit more for imaging applications. The somatostatin analogue affects biodistribution of the radionuclide, and therefore how effectively any treatment effect can be targeted. Changes affect which somatostatin receptor is most strongly targeted. For example, DOTA-lanreotide (DOTALAN) has a lower affinity for receptor 2 and a higher affinity for receptor 5 compared to DOTA-octreotide (DOTATOC).
Portugal's road network includes a system of 48 motorways, which, as of 2023, ranked as the seventh largest among 42 European countries. The busiest Portuguese airports are Lisbon Airport, Porto Airport, Faro Airport, Madeira Airport, and Ponta Delgada Airport. As of 2024, passenger and freight rail transport in Portugal operated on 2,526 km (1,570 mi) of active railway lines, with passenger services operated mainly by Comboios de Portugal (CP). The Port of Sines serves as Portugal's foremost container port and leads the country in cargo tonnage. As of 2023, two-thirds of Portugal's energy supply was imported, representing the 11th-highest level of energy dependency in the European Union. The country is pursuing energy transition and has invested in the development of renewable energy sources such as the Aguçadoura Wave Farm. Portugal has expanded the role of renewable sources in its energy sector, with renewables accounting for 35.2% of energy consumption, as of 2023 up from 21.9% in 2007, and 78.1% of total installed capacity, compared with 59.3% in 2014. In 2021, the country completed the phase-out of coal-fired generation.
The perianth is undifferentiated (perigonium) and biseriate (two whorled), formed from six tepals arranged into two separate whorls of three parts (trimerous) each, although Scoliopus has only three petals, free from the other parts, but overlapping. The tepals are usually petaloid (petal like) and apotepalous (free) with lines (striate) or marks in other colors or shades. The perianth is either homochlamydeous (all tepals equal, e.g. Fritillaria) or dichlamydeous (two separate and different whorls, e.g. Calochortus) and may be united into a tube. Nectar is produced in perigonal nectaries at the base of the tepals. The androecium consists of six stamens in two trimerous whorls, with free filaments, usually epiphyllous (fused to tepals) and diplostemonous (outer whorl of stamens opposite outer tepals and the inner whorl opposite inner tepals), although Scoliopus has three stamens opposite the outer tepals. The attachment of the anthers to the filaments may be either peltate (to the surface) or pseudo-basifixed (surrounding the filament tip, but not adnate, that is not fused) and dehisce longitudinally and are extrorse (dehiscing away from center). The pollen is usually monosulcate (single groove), but may be inaperturate (lacking aperture: Clintonia, some Tulipa spp.) or operculate (lidded: Fritillaria, some Tulipa spp.), and reticulate (net patterned: Erythronium, Fritillaria, Gagea, Lilium, Tulipa).
epitope Also antigenic determinant. The specific site or region within an antigenic macromolecule such as a protein or carbohydrate which is recognized by B or T cells of the immune system, against which a specific antibody is produced, and with which the antibody's paratope specifically interacts or binds. In proteins, epitopes are typically motifs of 4–5 amino acid residues, sequential or discontiguous, which by virtue of the distinct spatial conformation they adopt upon protein folding are able to uniquely interact with a particular paratope. In this sense they may be considered binding sites, though they do not necessarily overlap with ligand binding sites and need not be in any way relevant to the protein's normal function. Very large molecules may have multiple epitopes, each of which is recognized by a different antibody.
Sources: en.wikipedia.org
The peptide bonds in the chain are polar, i.e. they have separated positive and negative charges (partial charges) in the carbonyl group, which can act as hydrogen bond acceptor and in the NH group, which can act as hydrogen bond donor. These groups can therefore interact in the protein structure. Proteins consist mostly of 20 different types of L-α-amino acids (the proteinogenic amino acids). These can be classified according to the chemistry of the side chain, which also plays an important structural role. Glycine takes on a special position, as it has the smallest side chain, only one hydrogen atom, and therefore can increase the local flexibility in the protein structure. Cysteine in contrast can react with another cysteine residue to form one cystine and thereby form a cross link stabilizing the whole structure. Protein structure arises from a sequence of secondary structure elements, such as α helices and β sheets. In secondary structures, regular patterns of H-bonds are formed between the main chain NH and CO groups of spatially neighboring amino acids, and the amino acids have similar Φ and ψ angles.
==== Egypt ==== In an extension of a bilateral dispute between Ethiopia and Egypt over the Grand Ethiopian Renaissance Dam, Ethiopian government websites have been hacked by the Egypt-based hackers in June 2020.
=== Ra === Efraim Racker (1913–1991). Austrian-American biochemist at Cornell University, notable for work on ATP synthase. Member Natl. Acad. Sci. USA. George Radda FRS (1936–2024). Hungarian biochemist at Oxford University, known for applying nuclear magnetic resonance to complex biological material, and many other contributions. Ronald T. Raines (b. 1958). American biochemist at the University of Wisconsin–Madison and MIT, known for work on enzymes and other proteins. Venkatraman Ramakrishnan FRS (President) (b. 1952). Indian-British-American structural biologist at the MRC Laboratory of Molecular Biology, Cambridge, known for work on the ribosome. Nobel Prize in Chemistry in 2009. Philip Randle (1926–2006). British biochemist at the University of Bristol known for work on diabetes. Samuel Mitja Rapoport (1912–2004). Austrian and German biochemist at the Humboldt University, Berlin noted for studies of mitochondria, and for discovering a method for preserving blood for transfusions. Leader of biochemistry in the German Democratic Republic. Member of the German Academy of Sciences at Berlin. Tom Rapoport (b. 1947). German-American cell biologist at Harvard Medical School who studies protein transport in cells.
Hypertension, including hypertensive crises have been reported. QT interval prolongation and torsades de pointes have been reported. Thrombotic microangiopathy has been reported. Thrombotic thrombocytopenic purpura has been reported. Haemolytic uremic syndrome has been reported. Haematologic parameter alterations have been reported in 31–37% of patients. Events of cardiac dysfunction (decreased left ventricular ejection fraction and congestive heart failure) have been observed. Fatal haemorrhage, arterial and venous thrombotic events and perforations in the gastrointestinal tract have been observed in randomized clinical trials.
This competition could alter the post-transcriptional gene regulation (PTGR) of ADME-related genes, leading to indirect modulation of the expression of drug-metabolizing enzymes or transporters and causing DDIs with co-administered drugs. Short hairpin RNAs (shRNAs) may additionally compete with pre-miRNAs for the nuclear export protein Exportin-5 (XPO5) and the cytoplasmic ribonuclease Dicer, disrupting global miRNA biogenesis and posing further DDI risk. The U.S. Food and Drug Administration has issued guidance specific to oligonucleotide therapeutics, recommending assessment of QTc interval prolongation, immunogenicity, organ-impairment effects on PD endpoints, and the potential for RNAi machinery competition as part of the DDI risk framework for this drug class.
Sources: en.wikipedia.org
Laboratories commonly use liquid chromatography coupled with mass spectrometry to detect SR9009. The method can identify the compound and estimate concentration in a sample. Detection limits depend on the matrix and instrument.
Research-grade purity indicates a supplier's measured percentage of the intended compound. It does not guarantee safety, sterility, or suitability for human consumption. Buyers should request a certificate of analysis with chromatograms and test methods.
Sports regulators prohibit SR9009 because it is a non-approved substance with potential performance-altering effects. Its presence can be detected in anti-doping testing. Athletes are responsible for substances found in their samples.
SR9009 is a synthetic small molecule studied as an agonist of the REV-ERB nuclear receptors. It is not an approved medicine, and its effects in humans are not well characterized.